ASKA Pharmaceutical Holdings Co.,Ltd. (4886.T)
JPY 2041.0
(-0.34%)
JPY 2041.0
(-0.34%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 9.48 Billion JPY | -24.86% |
| 2022 | 12.62 Billion JPY | -10.13% |
| 2021 | 14.04 Billion JPY | -14.33% |
| 2020 | 16.39 Billion JPY | -0.15% |
| 2019 | 16.41 Billion JPY | -0.3% |
| 2018 | 16.46 Billion JPY | 458.24% |
| 2017 | 2.95 Billion JPY | -20.27% |
| 2016 | 3.7 Billion JPY | -35.18% |
| 2015 | 5.7 Billion JPY | 317.86% |
| 2014 | 1.36 Billion JPY | -12.27% |
| 2013 | 1.55 Billion JPY | -12.63% |
| 2012 | 1.78 Billion JPY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 8.26 Billion JPY | -12.86% |
| 2024 Q2 | 7.64 Billion JPY | -7.5% |
| 2023 Q2 | 10.32 Billion JPY | -3.05% |
| 2023 FY | 9.48 Billion JPY | -24.86% |
| 2023 Q4 | 9.48 Billion JPY | -6.14% |
| 2023 Q3 | 10.1 Billion JPY | -2.13% |
| 2023 Q1 | 10.65 Billion JPY | -15.63% |
| 2022 Q3 | 12.97 Billion JPY | 0.58% |
| 2022 Q4 | 12.62 Billion JPY | -2.69% |
| 2022 FY | 12.62 Billion JPY | -10.13% |
| 2022 Q1 | 13.24 Billion JPY | -5.7% |
| 2022 Q2 | 12.89 Billion JPY | -2.63% |
| 2021 FY | 14.04 Billion JPY | -14.33% |
| 2021 Q3 | 14.41 Billion JPY | -5.26% |
| 2021 Q1 | 15.59 Billion JPY | -4.88% |
| 2021 Q4 | 14.04 Billion JPY | -2.57% |
| 2021 Q2 | 15.21 Billion JPY | -2.43% |
| 2020 Q2 | 14.97 Billion JPY | -13.19% |
| 2020 FY | 16.39 Billion JPY | -0.15% |
| 2020 Q4 | 16.39 Billion JPY | -2.09% |
| 2020 Q1 | 17.24 Billion JPY | 5.02% |
| 2020 Q3 | 16.74 Billion JPY | 11.86% |
| 2019 Q2 | 19.89 Billion JPY | -2.57% |
| 2019 Q3 | 19.64 Billion JPY | -1.26% |
| 2019 FY | 16.41 Billion JPY | -0.3% |
| 2019 Q1 | 20.41 Billion JPY | 23.99% |
| 2019 Q4 | 16.41 Billion JPY | -16.41% |
| 2018 Q4 | 16.46 Billion JPY | 0.26% |
| 2018 Q2 | 17.47 Billion JPY | 48.41% |
| 2018 Q1 | 11.77 Billion JPY | 299.15% |
| 2018 FY | 16.46 Billion JPY | 458.24% |
| 2018 Q3 | 16.42 Billion JPY | -6.01% |
| 2017 Q1 | 3.52 Billion JPY | -4.73% |
| 2017 FY | 2.95 Billion JPY | -20.27% |
| 2017 Q4 | 2.95 Billion JPY | -6.35% |
| 2017 Q3 | 3.15 Billion JPY | -5.26% |
| 2017 Q2 | 3.32 Billion JPY | -5.67% |
| 2016 Q1 | 3.93 Billion JPY | -31.1% |
| 2016 FY | 3.7 Billion JPY | -35.18% |
| 2016 Q2 | 4.1 Billion JPY | 4.35% |
| 2016 Q4 | 3.7 Billion JPY | -5.83% |
| 2016 Q3 | 3.92 Billion JPY | -4.26% |
| 2015 Q2 | 2.98 Billion JPY | 65.21% |
| 2015 Q1 | 1.8 Billion JPY | 32.36% |
| 2015 Q4 | 5.7 Billion JPY | 3.09% |
| 2015 Q3 | 5.53 Billion JPY | 85.37% |
| 2015 FY | 5.7 Billion JPY | 317.86% |
| 2014 Q4 | 1.36 Billion JPY | -8.63% |
| 2014 Q2 | 1.49 Billion JPY | -23.84% |
| 2014 Q1 | 1.96 Billion JPY | 26.08% |
| 2014 Q3 | 1.49 Billion JPY | 0.0% |
| 2014 FY | 1.36 Billion JPY | -12.27% |
| 2013 FY | 1.55 Billion JPY | -12.63% |
| 2013 Q1 | 1.83 Billion JPY | 3.09% |
| 2013 Q3 | 1.66 Billion JPY | 15.41% |
| 2013 Q4 | 1.55 Billion JPY | -6.37% |
| 2013 Q2 | 1.44 Billion JPY | -21.56% |
| 2012 Q4 | 1.78 Billion JPY | 0.0% |
| 2012 Q3 | - JPY | 0.0% |
| 2012 Q2 | - JPY | 0.0% |
| 2012 FY | 1.78 Billion JPY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 16.89 Billion JPY | 43.846% |
| Takeda Pharmaceutical Company Limited | 4843.75 Billion JPY | 99.804% |
| Sumitomo Pharma Co., Ltd. | 418.88 Billion JPY | 97.736% |
| Shionogi & Co., Ltd. | 11.62 Billion JPY | 18.373% |
| Wakamoto Pharmaceutical Co.,Ltd. | 100.52 Million JPY | -9335.088% |
| Nippon Shinyaku Co., Ltd. | 2.87 Billion JPY | -230.258% |
| Kaken Pharmaceutical Co., Ltd. | 3.85 Billion JPY | -146.364% |
| Eisai Co., Ltd. | 206.74 Billion JPY | 95.412% |
| Morishita Jintan Co., Ltd. | 425 Million JPY | -2131.765% |
| Hisamitsu Pharmaceutical Co., Inc. | 2.1 Billion JPY | -351.667% |
| Mochida Pharmaceutical Co., Ltd. | 369 Million JPY | -2470.461% |
| Fuso Pharmaceutical Industries,Ltd. | 12.72 Billion JPY | 25.444% |
| Nippon Chemiphar Co., Ltd. | 16.98 Billion JPY | 44.143% |
| Tsumura & Co. | 79.69 Billion JPY | 88.098% |
| Kissei Pharmaceutical Co., Ltd. | 1.72 Billion JPY | -449.218% |
| Torii Pharmaceutical Co., Ltd. | 244 Million JPY | -3787.295% |
| Towa Pharmaceutical Co., Ltd. | 202.35 Billion JPY | 95.313% |
| Fuji Pharma Co., Ltd. | 28.94 Billion JPY | 67.234% |
| Zeria Pharmaceutical Co., Ltd. | 47.58 Billion JPY | 80.068% |
| KYORIN Holdings, Inc. | 20.94 Billion JPY | 54.717% |
| Taiko Pharmaceutical Co.,Ltd. | 3.8 Billion JPY | -149.015% |
| Daito Pharmaceutical Co.,Ltd. | 8.71 Billion JPY | -8.785% |
| SymBio Pharmaceuticals Limited | - JPY | -Infinity% |
| MedRx Co., Ltd | - JPY | -Infinity% |
| Mizuho Medy Co.,Ltd. | - JPY | -Infinity% |
| Solasia Pharma K.K. | 60 Million JPY | -15708.333% |
| Modalis Therapeutics Corporation | 412.5 Million JPY | -2199.394% |
| Sawai Group Holdings Co., Ltd. | 82.89 Billion JPY | 88.557% |
| Cyfuse Biomedical K.K. | 913 Million JPY | -938.883% |
| Toho Holdings Co., Ltd. | 30.24 Billion JPY | 68.638% |
| Koa Shoji Holdings Co.,Ltd. | 2.82 Billion JPY | -235.718% |